Denovo Biopharma's AI-Discovered Biomarker Patent Unlocks New Hope for Treatment-Resistant Depression

SAN DIEGO, CA – April 29, 2026 – Denovo Biopharma, a company at the vanguard of precision medicine for neurological disorders, has secured a pivotal U.S. patent that could reshape the treatment landscape for one of psychiatry's most formidable challenges: treatment-resistant depression (TRD). The patent protects a novel genetic biomarker, discovered using artificial intelligence, that identifies patients likely to respond to the company's drug, liafensine (DB104). This development not only offers a new lifeline to a desperate patient population but also grants Denovo a powerful strategic advantage with market exclusivity protected until 2043.

The U.S. Patent and Trademark Office issued U.S. Patent No. 12,612,261, which covers the use of the DGM4™ biomarker to guide treatment with liafensine. This move solidifies Denovo’s intellectual property and validates its unique approach of rescuing promising but previously failed drugs by matching them to the right patients.

A New Era for Psychiatric Treatment

Major depressive disorder (MDD) affects an estimated 280 million people worldwide, but for roughly one-third of them, the path to relief is a frustrating cycle of trial and error. These individuals, diagnosed with treatment-resistant depression, fail to respond to at least two different antidepressant medications. The result is a prolonged struggle with debilitating symptoms, significant personal suffering, and one of the highest economic burdens among all psychiatric conditions. For decades, the standard of care has involved switching between medications with similar mechanisms of action, hoping one will eventually work.

Denovo Biopharma aims to replace this guesswork with precision. By identifying a specific genetic signature, the company can predict who will benefit from liafensine, marking a significant step toward personalized psychiatry.

“The patent issuance for the DGM4 biomarker represents a significant step in strengthening our DB104 intellectual property portfolio and reinforces our mission to redefine the treatment of TRD, a difficult-to-treat CNS disorder that impacts millions of patients globally,” said Wen Luo, PhD, Denovo’s Chief Executive Officer, in a statement. He noted that the patent builds upon the drug's successful Phase 2b study and FDA Fast Track Designation, calling it a milestone that “underscores its potential to transform how we address TRD through a patient-specific, biomarker-driven approach.”

The Science of Specificity: From Failed Drug to Targeted Therapy

The story of liafensine is a testament to the power of this new approach. The drug, a first-in-class triple reuptake inhibitor that targets serotonin, norepinephrine, and dopamine, was originally developed by Bristol Myers Squibb. Despite a superior safety profile demonstrated across 14 clinical trials, liafensine failed to show significant efficacy in a general population of TRD patients, and its development was halted.

Instead of a dead end, Denovo saw an opportunity. The company licensed liafensine and deployed its proprietary artificial intelligence platform, the Denovo Genomic Marker (DGM™) system. By conducting a whole genome scan on archived samples from patients in the original trials, the AI platform identified a previously unknown genetic biomarker—a single nucleotide polymorphism (SNP) in the ANK3 gene—that correlated strongly with a positive response to the drug. This biomarker was named DGM4™.

The ANK3 gene is already well-known to the scientific community for its crucial role in neuronal signaling and its established links to psychiatric conditions like bipolar disorder and depression, lending strong biological plausibility to the discovery. Armed with this knowledge, Denovo launched the ENLIGHTEN Phase 2b trial, prospectively enrolling only TRD patients who tested positive for the DGM4 biomarker.

The results were a resounding success. In this targeted population, liafensine demonstrated robust efficacy and a favorable safety profile, achieving what had been impossible in a broader patient group. The findings were significant enough to be published in the prestigious peer-reviewed journal JAMA Psychiatry, lending critical scientific validation to Denovo's biomarker-driven strategy.

Patent Power and Market Position

The issuance of U.S. Patent No. 12,612,261 is a major business coup. Unlike traditional patents on a drug's chemical composition, which often have a limited lifespan, this method-of-use patent protects the process of using the DGM4 biomarker to guide liafensine treatment. Because liafensine itself is no longer a new chemical entity, this biomarker-based protection is essential. Securing exclusivity until 2043 gives Denovo an exceptionally long commercial runway, free from generic competition in its target market.

This intellectual property is critical in the lucrative TRD market, which was valued at over $2.6 billion in 2023 and is projected to more than double in the next decade. By focusing on the DGM4-positive subpopulation, Denovo can target its commercial efforts, potentially achieving higher success rates and market penetration within that group. It also positions Denovo as a highly attractive partner for larger pharmaceutical firms looking to enter the precision psychiatry space.

More broadly, this patent serves as a powerful proof-of-concept for Denovo's entire business model. It validates its AI-driven DGM™ platform as a tool that can unlock hidden value in shelved pharmaceutical assets, de-risking future projects in its pipeline which spans CNS diseases and oncology.

What This Means for Patients

Beyond the corporate strategy and market dynamics, the most significant impact of this development is the hope it offers to patients. For the millions of people living with TRD, the journey is often characterized by despair and a feeling of being beyond help. The current trial-and-error approach can take months or years, during which patients endure continued suffering and the side effects of ineffective medications.

A biomarker-guided approach promises to change this paradigm. With a simple genetic test, doctors could identify DGM4-positive patients and prescribe liafensine with a much higher degree of confidence. This would not only increase the likelihood of a successful outcome but also spare patients the physical and emotional toll of failed treatment attempts.

The development of a companion diagnostic test to identify the DGM4 biomarker will be a necessary and critical next step on the path to commercialization. For a population that has long awaited a breakthrough, the combination of a targeted drug and a predictive test represents a tangible move away from guesswork and toward a future of truly personalized mental healthcare.